Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Investor Presentation (October 2026)
38 slides from Radiopharm Theranostics's investor presentation, October 2026
Slide 1: A Multi-Asset, First-in-Class Radiopharmaceutical Platform
NASDAQ: RADX / ASX: RAD A Multi-Asset, First-in-Class Radiopharmaceutical Platform Protein-engineered radiotherapies targeting validated oncology pathways COMPANY PRESENTATION October 2026 1
Slide 2: Notice & Disclaimer
Notice & Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889
Slide 3: Investment highlights
Investment highlights T H E T H E S I S : F O C U S E D O N T H E R A P E U T I C S ; N O N - D I L U T I V E V A L U E C R E A T I O N F R O M D I A G N O ST IC S Differentiated platform Near-term catalysts Four clinical-stage Therapeutic assets Four Therapeutic dose-escalation studies Two Imaging
Slide 4: Company Pipeline in Clinical Stage
Company Pipeline in Clinical Stage PROGRAM INDICATION ISOTOPE PHASE I PHASE II PHASE III CATALYSTS Dose-escalation completion RAD 202 HER2 + solid tumors 177Lu H1 2027 Dose-escalation completion RAD 204 PDL1+ solid tumors 177Lu H1 2027 Dose-escalation completion RV 01 B7-H3+ solid tumors 177Lu H2 20
Slide 5: RAD202 — HER2-targeted radiotherapy
RAD 202 THERAPEUTIC RAD202 — HER2-targeted radiotherapy Bringing radiotherapy to one of the largest targetable oncology populations THE HER2 OPPORTUNITY ESTABLISHED TARGET BROADER POPULATION POSITIONING HER2 Beyond HER2+ Post-Enhertu One of the most established targets in Expanding into HER2-low and
Slide 6: Extending HER2 targeting beyond current modalities
RAD 202 THERAPEUTIC Extending HER2 targeting beyond current modalities A 177Lu-radioconjugate targeting HER2 via a single-domain nanobody — distinct from antibodies and ADCs THE CONSTRUCT Anti-HER2 nanobody binds linker ~15 kDa · 2.5 × 4 nm Nanomolar affinity HER2 sdAb ¹⁷⁷Lu Distinct epitope vs tras
Slide 7: Phase I dose escalation with a favorable safety profile
RAD 202 THERAPEUTIC Phase I dose escalation with a favorable safety profile First three cohorts completed with no DLTs — Dose Level 4 dosed at 180 mCi 180 mCi 6.7 GBq TRIAL DESIGN 130 mCi DL4 4.8 GBq PRIMARY OBJECTIVES (PHASE 1) 75 mCi DL3 • Safety & tolerability of ¹⁷⁷Lu-RAD202 2.7 GBq • Recommende
Slide 8: Cohort #3 (130mCi): ongoing assessment for early efficacy signal
Cohort #3 (130mCi) : ongoing assessment for early efficacy signal SAFETY ASSESSMENT: COMPLETED 5 patients dosed, NO DLT, Favorable safety profile CLINICAL EFFICACY: ONGOING • 3/5 Patients with Stable Disease are continuing to complete the 4-cycle regimen • 1 Patient with 12% tumor reduction after Do
Slide 9: Cohort #4 (180 mCi): started with fast recruitment rate
Cohort #4 (180 mCi): started with fast recruitment rate SAFETY ASSESSMENT: ongoing EFFICACY ASSESSMENT: ongoing • 1st Patient with 9% tumor reduction after Dose #1 HER2+ tumor type Enrolled Progression free interval Tumor Volume RECIST -status 10% Stable Disease - scheduled for dose #2 5% Tumor size
Slide 10: RAD202 Investment Case
RAD 202 THERAPEUTIC RAD202 Investment Case Post-Enhertu SoC: tucatinib + trastuzumab + capecitabine HER2 is one of the largest and most validated oncology targets RAD 202 SoC Trending towards SoC outcomes ORR = n/a 6 Patients currently ORR= 20% -25% under treatment in DL#3 & DL#4 Avg PFS = 3+ mo Avg
Slide 11: RAD204 — First-in-class PD-L1 targeted radiotherapy
RAD 204 THERAPEUTIC RAD204 — First-in-class PD-L1 targeted radiotherapy Validated immuno-oncology target First-in-class PD-L1 targeted 177Lu radiotherapy POTENTIAL POSITIONING LEAD INDICATION EXPANSION Post-IO NSCLC Multiple solid tumors High unmet-need setting after immunotherapy Across PD-L1–expre
Slide 12: PD-L1 targeting beyond antibodies & ADCs
RAD 204 THERAPEUTIC PD-L1 targeting beyond antibodies & ADCs RAD 204 A 177Lu-radioconjugate targeting PD-L1 — a distinct modality vs checkpoint antibodies and ADCs THE CONSTRUCT binds linker Sub-nanomolar affinity Distinct epitope vs atezolizumab PD-L1 sdAb 177Lu Tumor target Single-domain targeting
Slide 13: RAD204 (PDL-1 targeting): early efficacy signal
RAD 204 THERAPEUTIC RAD204 (PDL-1 targeting): early efficacy signal First patient dosed at Cohort 3 (90 mCi) — dose escalation ongoing under a Bayesian (BOIN) design TRIAL DESIGN 90 mCi 3.3 GBq PRIMARY OBJECTIVES • Safety & tolerability of ¹⁷⁷Lu-RAD204 60 mCi DL3 2.2 GBq • Recommended Phase 2 dose 3
Slide 14: RAD204: early clinical activity
RAD 204 THERAPEUTIC RAD204: early clinical activity First patient at 90 mCi achieved a confirmed RECIST Partial Response with durable (9+ months) tumor shrinkage Partial Response 9.5 months PFS Progressive Disease 4 months PFS RECIST Confirmed (Pt #7) Before progressing New lesion emerged Before pro
Slide 15: Patient #7 — first patient treated at 90 mCi
RAD 204 THERAPEUTIC Patient #7 — first patient treated at 90 mCi Durable confirmed RECIST partial response across multiple cycles CORONAL CT · RLL PRIMARY Baseline NSCLC — progressed after multiple prior therapies October ‘25 • External-beam radiotherapy • Chemotherapy (carboplatin, taxane) Expected
Slide 16: Trending towards superior results vs standard of care
RAD 204 THERAPEUTIC Trending towards superior results vs standard of care Confirmed PR Kidney uptake not limiting Patient #7 at DL#3 · sustained PFS dose escalation Post-IO NSCLC · SoC = VEGFR + chemo DOSE LEVEL 3 · 90 mCi (3.3 GBq) · NSCLC #7 Partial Response RECIST(confirmed) PR 9.5 mo PFS RAD 204
Slide 17: RAD204 Investment Case
RAD 204 THERAPEUTIC RAD204 Investment Case Targeted radiotherapy introduces a new PD-L1 is the largest and most validated principle combining two synergistic immuno-oncology target mechanisms of action Addressable market (US, post-IO NSCLC) Platform enables continued optimization 40,000–65,000 acros
Slide 18: RV 01 & RAD 402 Clinical Development
RV 01 & RAD 402 Clinical Development Dose escalation progressing well
Slide 19: Summary
Summary 1) VALUE CREATION Through Partnering Partnering process RAD 101 & RAD 301 Non-dilutive monetization ongoing Imaging trials completed successfully Letter of Intent from multiple players Upfront, milestone, and royalties as base deal expected soon plan 2 ) F O C U S E D R E S O U R CE S O N I
Slide 20: Thank You
Thank You www.radiopharmtheranostics.com
Slide 21: RAD 101 – RAD 301 Partnering project ongoing
RAD 101 – RAD 301 Partnering project ongoing 21
Slide 22: Imaging lead asset — RAD101
RAD 101 DIAGNOSTIC Imaging lead asset — RAD101 First-in-class PET tracer with high probability of success — near-term value and optionality THE NEED THE MARKET High unmet Need - SoC MRI falls short 300,000 Early identification of recurrent brain metastases is urgent need in ~300,000 new brain-metast
Slide 23: RAD101 Phase IIb — primary endpoint readout
RAD 101 DIAGNOSTIC RAD101 Phase IIb — primary endpoint readout Primary endpoint met — high concordance with MRI. 93% PRIMARY ENDPOINT Concordance with MRI 28 / 30 patients concordant SUCCESSFULLY ACHIEVED *3/30 Patient data not yet available SECONDARY ENDPOINT · INTERIM ANALYSIS SENSITIVITY INTERIM
Slide 24: RAD101 - Next steps to Phase 3
RAD 101 DIAGNOSTIC RAD101 - Next steps to Phase 3 A clear, de-risked path to a Phase 3 ready to start in Q4 2026 May 2026 Oct 1st 2026 Oct 30th 2026 Q1 2027 MILESTONES Advisory Board FDA protocol meeting FDA meeting feedback Phase 3 Supportive of Phase 3 Align on trial design Ready to initiate Trial
Slide 25: Imaging asset — RAD301
RAD 301 DIAGNOSTIC Imaging asset — RAD301 THE NEED THE MARKET High unmet Need - SoC falls short 15,000 Early identification of pancreatic lesions is urgent need in PDAC patients ~15,000 new PDAC patients each year (US) THE ASSET THE DATA Potential first-in-class PET tracer Phase 1 positive read-out
Slide 26: RAD 402 – RV 01 – RAD 101 – RAD 301
RAD 402 – RV 01 – RAD 101 – RAD 301 26
Slide 27: BETABART (RV01) — First-in-class selective anti-B7H3
RV 01 THERAPEUTIC BETABART (RV01) — First-in-class selective anti-B7H3 A selective anti-B7H3 monoclonal antibody in clinical development THE CONSTRUCT B7H3 mAb ¹⁷⁷Lu Target Antibody Payload Selective for tumor 4Ig-B7H3 Engineered mAb biodistribution Engineered mAb — optimized biodistribution Isotope
Slide 28: Phase I basket trial underway
RV 01 THERAPEUTIC Phase I basket trial underway First-in-class 177Lu-RV01 (BETABART) — dose escalation across a multi-tumor basket Enrollment proceeding very well: first patient dosed 2/2026 · first cohort completed in <5 months · TRIAL DESIGN multiple tumor types enrolled PRIMARY OBJECTIVES (PHASE
Slide 29: B7H3 radiotherapies: competitive landscape
RV 01 THERAPEUTIC B7H3 radiotherapies: competitive landscape Competing approaches: mini-proteins & peptides RAD approach: full mAb with engineered biodistribution Phase I: Phase I Company Program Molecule Indication Isotope Pre-IND IND granted first patient completed dosed mAb Radiopharm 1 basket tr
Slide 30: RAD402 — First-in-class KLK3-targeting mAb
RAD402 THERAPEUTIC RAD402 — First-in-class KLK3-targeting mAb A highly differentiated 161Tb radiotherapy approach in prostate cancer Advantage of 161Tb radiotherapy THE CONSTRUCT KLK3 mAb ¹⁶¹Tb Target Antibody Payload Prostate-specific KLK3 target Expressed in >90% of tumors · validated PSA biology
Slide 31: Addressing the limitations of PSMA-based radiotherapy
RAD402 THERAPEUTIC Addressing the limitations of PSMA-based radiotherapy KLK3: a cleaner, more selective target for prostate cancer than PSMA Relative Expression Levels 31
Slide 32: RAD402 clinical status
RAD402 THERAPEUTIC RAD402 clinical status First-in-class 161Tb program — Phase I dose escalation underway Enrollment proceeding very well: first patient dosed 3/2026 · first cohort completed in ~4 TRIAL DESIGN months PRIMARY OBJECTIVES (PHASE 1) Phase I — Treatment (dose escalation) • Safety & toler
Slide 33: TEAM
TEAM 33
Slide 34: Leadership with proven pharma and radiopharma track record
LEADERSHIP WITH PROVEN PHARMA AND RADIOPHARMA TRACK RECORD EXPERIENCED DEVELOPMENT AND REGULATORY TEAM Clinical Regulatory Riccardo Canevari Dr. Dimitris Voliotis CEO CMC Radiochemistry CMO Prior Chief Prior CDO, Global Head Quality Preclinical Commercial Officer Clinical Development at at AAA, Nova
Slide 35: Chairman and Board
Chairman and Board Paul Hopper Executive Chairman Ian Turner Hester Larkin Noel Donnelly • Founder of Radiopharm Theranostics Ltd. • 25 years experience as a life-sciences entrepreneur • Founder, Chairman, non-executive director or C E O of more than fifteen companies in the US, Australia a n d Asia
Slide 36: ISOTOPE SUPPLY CHAIN
ISOTOPE SUPPLY CHAIN 36
Slide 37: Isotope Selection and Supply Chain
Isotope Selection and Supply Chain Beta-Emitters: Best proven therapeutic index, secure and reliable sourcing 177-Lutetium 161-Terbium Beta Particles B e t a & Au g e r Particles Most used therapeutic isotope Innovative dual atomic particle functionality combining the benefits of Beta cross-fire eff
Slide 38: Nanobody vs Conventional (IgG) Antibody
RAD 202 / 204 Nanobody vs Conventional (IgG) Antibody Structure, Size & Key Differences 38
Radiopharm Theranostics — Investor Presentation (October 2026) on 6ix